S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer

Medicine (United States)

Volumn 96, Issue 30, 2017, Pages

  Zhong, Sheng ^a   Qie, Shuai ^b   Yang, Liu ^a   Yan, Qi ^c   Ge, Linna ^d   Wang, Zhongfeng ^a  

^a JILIN UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c QIQIHAR MEDICAL UNIVERSITY   (China)

^d Jixi Mining General Hospital   (China)

Author keywords

advanced pancreatic cancer; combination therapy; irinotecan; leucovorin; monotherapy; oxaliplatin; S 1; second line chemotherapy

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG COMBINATION; DRUG RESISTANCE; PANCREATIC NEOPLASMS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; OXONIC ACID; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEGAFUR;

EID: 85026356411     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007611     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hirooka Y, Itoh A, Kawashima H, et al. Diagnosis of pancreatic disorders using contrast-enhanced endoscopic ultrasonography and endoscopic elastography. Clin Gastroenterol Hepatol 2009; 7(Suppl): S63-7.
3. Bond-Smith G, Banga N, Hammond TM, et al. Pancreatic adenocarcinoma. BMJ 2012; 344: e2476.
4. Burris HAIII, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefitwithgemcitabine asfirst-line therapy forpatientswithadvanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
5. Conroy T, Desseigne F, YchouM, et al. (Bond-Smith, Banga, Hammond, & Imber, 2012)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
6. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-9.
7. UenoM, Okusaka T, Omuro Y, et al. Arandomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabinerefractory advanced pancreatic cancerdagger. Ann Oncol 2016; 27: 502-8.
8. Ge F, Xu N, Bai Y, et al. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, Phase II study. Oncologist 2014; 19: 1133-4.
9. Ohkawa S, Okusaka T, IsayamaH, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112: 1428-34.
10. Mizuno N, Yamao K, Komatsu Y, et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. J Clin Oncol 2013; 31: 264.
11. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009; 18: 335-48.
12. Ueno H, Ioka T, Ikeda M, et al. 2013 Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-8.
13. Nakai Y, Isayama H, Sasaki T, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 2012; 106: 1934-9.
14. Ozaka M, Matsumura Y, Ishii H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 2012; 69: 1197-204.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
16. Tsukioka S, Uchida J, Tsujimoto H, et al. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice. Mol Med Rep 2009; 2: 393c-8c.